The relatively higher PSA levels previously recorded for US-EA and US-AA controls either in the pre- or early PSA era being comparable to the PSA level of the current NZ-European controls may be a consequence of low level of PSA-based prostate cancer screening and subsequent procedures in prostate cancer diagnosis in NZ as recorded previously32,51. The gene discussed is KLK3; the disease is prostate cancer.